title: Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.
abstract: Fusions of antigen presenting cells and tumor cells have been investigated in animal models and phase I/II clinical trials as candidate cancer vaccines. In animal studies there have been numerous reports of induction of protective immunity against a wide range of tumor types. Results of clinical trials have been less dramatic, but tumor-specific immune responses have been reported in many patients, with clinical responses to the vaccination in a subset. In this commentary article, I review the current status of antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy.
authors.affiliation: Department of Infection; Immunity and Inflammation; University of Leicester; Leicester, UK; Department of Immunology; Leicester Royal Infirmary; Leicester, UK.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Browning
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D002459:Cell Fusion; D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D006822:Hybrid Cells / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines
keywords: antigen presenting cell; cancer; fusion; hybrid; tumour; vaccine